{"version":"1.0","type":"link","title":"Evaluating the toxicity profile of combination immune checkpoint inhibitors: a disproportionality analysis of real-world adverse events from the FDA Adverse Event Reporting System for tremelimumab, durvalumab, ipilimumab, and nivolumab.","author_name":"Li Z 외","author_url":"https://prs-insight.online/author/Li%20Z","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/119124","thumbnail_width":1200,"thumbnail_height":630}